Will generic hypertension guidelines reduce the proliferation of directives?

Heart

Volumn 93, Issue 7, 2007, Pages 775-777

  Staessen, Jan A ^a,b   O'Brien, Eoin ^c  

^a Studies Coordinating Centre   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETES MELLITUS; EDITORIAL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; METABOLIC DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; HUMANS; HYPERTENSION; PRACTICE GUIDELINES; RISK FACTORS;

EID: 34347217485     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.109512     Document Type: Editorial

References (19)

1. Higgins B, Williams B, Bakhshi L, et al. Management of hypertension in adults in primary care: partial update. London: Royal College of Physicians, 2006.
2. Joint British Societies' guidelines on prevention of cardiovascular diseases in clinical practice. Heart 2005;91(suppl V):1-52.
3. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.
4. Mann J, Arroll B, Carryer J, et al. Evidence-based best practice guideline. The assessment of cardiovascular risk. Wellington: New Zealand, 2003.
5. Chobanian AV, Bakris GL, Black BK, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
6. European Society of Hypertension/European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
7. Zhang H, Thijs L, Staessen JA. Blood pressure lowering for the primary and secondary prevention of stroke. Hypertension 2006;48:187-95.
8. Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005;28:385-407.
9. Verdecchia P, Reboldi G, Angeli A, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46:386-92.
10. O'Brien E, Asmar R, Beilin L, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005;23:697-701.
11. Kikuya M, Hansen TW, Thijs L, et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation. In press.
12. Emberson JR, Whincup PH, Morris RW, et al. Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur Heart J 2003;24:1719-26.
13. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-9.
14. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52.
15. Messerli FH, Bakris G, Ferrera RD, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens 2006;8:571-81.
16. Casas JP, Chua W, Loukogoergakis S, et al. Effects of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-33.
17. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure dependent and independent effects of agents thatinhibit the renin-angiotensin system. J Hypertens. In press.
18. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2005;43:963-9.
19. The EUROPA Study Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary heart disease: randomised double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.